Immuno Cure is a biotechnology company focused on developing immunotherapies for cancers, inflammatory, and infectious diseases using its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody Immune Blocking technology. The company is advancing two vaccines currently in first-in-human clinical trials to improve treatment outcomes for patients facing these serious health conditions.
Funding
$8.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatment options for cancers, inflammatory, and infectious diseases often have limited efficacy or significant side effects. There remains a need for novel immunotherapies that can improve patient outcomes for these serious health conditions.
Solution
Immuno Cure is developing immunotherapies based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody Immune Blocking technology platforms. The PD-1-enhanced DNA vaccine platform aims to stimulate a more robust and targeted immune response against disease cells. The Anti-Δ42PD1 Antibody Immune Blocking technology is designed to enhance the body's natural ability to fight disease by blocking inhibitory signals. These technologies are being applied to develop new treatments for cancers, inflammatory disorders, and infectious diseases.
Target Audience
The primary target audience includes patients with cancers, inflammatory disorders, and infectious diseases, as well as healthcare providers seeking innovative treatment options.
Features
- PD-1-enhanced DNA vaccine technology to stimulate targeted immune responses
- Anti-Δ42PD1 Antibody Immune Blocking technology to enhance the body's natural ability to fight disease
- Development of vaccines for cancers, inflammatory disorders, and infectious diseases
- Two vaccines currently in first-in-human clinical trials